Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy
Background: Circulating tumor DNA (ctDNA) is predictive of recurrence in resected stage III melanoma, yet its role in the neoadjuvant setting for clinical stage III (cSIII) is unclear. Objective: Assess the association between ctDNA and outcomes following neoadjuvant immunotherapy (IO) + targeted th...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2026-01-01
|
| Serie: | Therapeutic Advances in Medical Oncology |
| Accesso online: | https://doi.org/10.1177/17588359251412729 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|